Actualités sur l’utilisation des toxines botuliques
EMC - Podologie-Kinésithérapie · 2004
DOI: 10.1016/j.emck.2003.10.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMC - Podologie-Kinésithérapie, 2004. Verfasst von C Hugeron und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 93 Literaturangaben.
Abstract (Originalsprache)
Botulinum toxin is a neurotoxin produced by the anaerobic bacterium Clostridium botulinum. Of the seven serotypes (A through G), A, B, and E have been implicated in the occurrence of botulinism. Only A and B are used for therapeutic purposes. Botulinum toxins bind irreversibly to the presynaptic receptors at the neuromuscular junction, thereby inhibiting acetylcholine release. Although this permanently inactivates the neuromuscular junction, collaterals grow and form new junctions within a few weeks or months, so that the effect of the injections is temporary.
Zitieren
APA
Hugeron, C., & Denys, P. (2004). Actualités sur l’utilisation des toxines botuliques. EMC - Podologie-Kinésithérapie. https://doi.org/10.1016/j.emck.2003.10.001
Vancouver
Hugeron C, Denys P. Actualités sur l’utilisation des toxines botuliques. EMC - Podologie-Kinésithérapie. 2004. doi:10.1016/j.emck.2003.10.001
BibTeX
@article{Hugeron2004,
author = {Hugeron, C and Denys, P},
title = {Actualités sur l’utilisation des toxines botuliques},
journal = {EMC - Podologie-Kinésithérapie},
year = {2004},
doi = {10.1016/j.emck.2003.10.001}
}
EUVIMED